Cost-Utility Analysis of Triple Therapy with Inavolisib Versus Standard Dual Therapy in the Treatment of HR+ / HER2- Advanced Metastatic Breast Cancer with PIK3CA Gene Mutation
Author：CHEN Jiagen、 ZHU Tongming、 LI Wenqiang、 YI Jia、 SHEN Aizong
5 pages
